Efgartigimod for recent Guillain-Barré syndrome
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether an experimental drug called efgartigimod (given as an infusion) can help people with Guillain-Barré syndrome recover faster. It is for adults who recently developed symptoms and have significant weakness that affects their walking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with Guillain-Barré syndrome (a rare nerve disorder that causes weakness).
- Your symptoms started within the last 14 days.
- Your symptoms are severe enough that you have difficulty walking or are unable to walk, but you are not bedbound or on a ventilator.
- You have not had a previous bout of GBS.
- You are not living with active hepatitis B or C, HIV, or another serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood-based treatments for Guillain-Barré syndrome: one that filters antibodies from the blood (immunoadsorption) and one that uses donated antibodies (IVIG). Both aim to reduce nerve damage and speed up recovery, and researchers want to see which works better.
This trial tests a new medicine, tanruprubart (also called ANX005), for people with Guillain-Barré syndrome. It aims to see if the drug can help improve recovery when given soon after symptoms start.
This trial studies whether an inpatient rehabilitation program can help people with Guillain-Barré syndrome. It may be useful if you need structured therapy and support during recovery.
This trial tests whether noninvasive breathing support (like a mask or nasal prongs) can help people with Guillain-Barré syndrome who have trouble breathing. It aims to see if this approach can avoid the need for a breathing tube.
This trial tests a new medicine called efgartigimod for people with Guillain-Barré syndrome (GBS), a condition where the immune system attacks the nerves. The medicine aims to reduce the immune attack and help you recover faster. It is for people who started having GBS symptoms within the last 2 weeks and have moderate to severe symptoms.
This study tests a new investigational medicine called empasiprubart when added to the standard IVIg treatment for people with Guillain-Barré syndrome. It aims to see if adding this medicine can help improve recovery compared to IVIg alone.
Hear when a new Guillain Barré Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.